Improving clinical trial accrual by streamlining the referral process
暂无分享,去创建一个
[1] Michelle A. Mathiason,et al. Clinical trial accrual among new cancer patients at a community‐based cancer center , 2006, Cancer.
[2] B. Munos. Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.
[3] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[4] Peter J. Embi,et al. Development of an Electronic Health Record-based Clinical Trial Alert System to Enhance Recruitment at the Point of Care , 2005, AMIA.
[5] Jon D. Miller,et al. Public attitudes toward participation in cancer clinical trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Prescott,et al. Barriers to participation in randomised controlled trials: a systematic review. , 1999, Journal of clinical epidemiology.
[7] P. LoRusso,et al. Accrual to breast cancer clinical trials at a university-affiliated hospital in metropolitan Detroit. , 1999, American journal of clinical oncology.
[8] M. Christian,et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] A. Gafni,et al. Why cancer patients enter randomized clinical trials: exploring the factors that influence their decision. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] L J Mahoney,et al. Reasons for non‐entry in randomized clinical trials for breast cancer: A single institutional study , 1992, Journal of surgical oncology.
[11] L. Beckett,et al. An Evaluation of Barriers to Accrual in the Era of Legislation Requiring Insurance Coverage of Cancer Clinical Trial Costs in California , 2004, Cancer journal.
[12] A. Towse,et al. The R&D Cost of a New Medicine , 2012 .
[13] Kevin B. Weiss,et al. Managing Complexity in Chronic Care: An overview of the VA State-of-the-Art (SOTA) Conference , 2007, Journal of General Internal Medicine.
[14] Peter J. Embi,et al. Physicians' perceptions of an electronic health record-based clinical trial alert approach to subject recruitment: A survey , 2008, BMC Medical Informatics Decis. Mak..
[15] J. Concato,et al. Vector Model of Complexity , 2008, Journal of general internal medicine.
[16] Van V. Brantner,et al. Estimating the cost of new drug development: is it really 802 million dollars? , 2006, Health affairs.
[17] D. Hunninghake,et al. Recruitment for controlled clinical trials: literature summary and annotated bibliography. , 1997, Controlled clinical trials.
[18] Lawrence B. Afrin,et al. Leveraging of Open EMR Architecture for Clinical Trial Accrual , 2003, AMIA.
[19] E. Fisher,et al. The accuracy of Medicare's hospital claims data: progress has been made, but problems remain. , 1992, American journal of public health.
[20] Jeroan J. Allison,et al. Patient Complexity: More Than Comorbidity. The Vector Model of Complexity , 2007, Journal of General Internal Medicine.
[21] L. Dyrbye,et al. Physician burnout: a potential threat to successful health care reform. , 2011, JAMA.
[22] E. DeLong,et al. Discordance of Databases Designed for Claims Payment versus Clinical Information Systems: Implications for Outcomes Research , 1993, Annals of Internal Medicine.
[23] R. Kravitz,et al. Frequent overcrowding in U.S. emergency departments. , 2001, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.
[24] Rosaline Joseph,et al. Viewpoints and concerns of a clinical trial participant , 1994, Cancer.
[25] I. Morrison. The Future of Physicians' Time , 2000, Annals of Internal Medicine.
[26] H. Quan,et al. Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database. , 2008, Health services research.
[27] Moon S. Chen,et al. Overcoming barriers to cancer clinical trial accrual , 2008, Cancer.
[28] E. Mansour,et al. Barriers to clinical trials: Part III: Knowledge and attitudes of health care providers , 1994, Cancer.
[29] R. Yancik,et al. Selection factors in clinical trials: results from the Community Clinical Oncology Program Physician's Patient Log. , 1987, Cancer treatment reports.
[30] Van V. Brantner,et al. Estimating the Costs of New Drug Development: Is it really $802m? , 2005 .
[31] D. Gandara,et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Joel Lexchin,et al. The cost of drug development: a systematic review. , 2011, Health policy.
[33] J. DiMasi,et al. Drug development costs when financial risk is measured using the Fama-French three-factor model. , 2009, Health economics.
[34] Clement J. McDonald,et al. What can natural language processing do for clinical decision support? , 2009, J. Biomed. Informatics.
[35] P M Ellis,et al. Attitudes towards and participation in randomised clinical trials in oncology: a review of the literature. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] Shiraz I Mishra,et al. Recruitment and participation in clinical trials: socio-demographic, rural/urban, and health care access predictors. , 2006, Cancer detection and prevention.